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The differential diagnosis and the identification of the source
of ACTH in occult ectopic Cushing’s syndrome due to a bron-
chial carcinoid still represents a challenge for the endocri-
nologist. We report our experience in six patients with occult
bronchial carcinoid in whom extensive hormonal, imaging,
and scintigraphic evaluation was performed. All patients pre-
sented with hypercortisolism associated with high plasma
ACTH values. The CRH test and high dose dexamethasone
suppression test suggested an ectopic source of ACTH in three
of six patients. During bilateral inferior petrosal sinus sam-
pling, none of the patients showed a central to peripheral
ACTH gradient. At the time of diagnosis, none of the patients
had radiological evidence of the ectopic source of ACTH,
whereas pentetreotide scintigraphy identified the lesion in
two of four patients. Finally, a chest computed tomography
scan revealed the presence of a bronchial lesion in all patients,
and pentetreotide scintigraphy identified four of six lesions.
In all patients a bronchial carcinoid was found and removed.
In one patient with scintigraphic evidence of residual disease
after two operations, radioguided surgery, using a hand-held
 probe after iv administration of radiolabeled pentetreotide,
was performed; this allowed detection and removal of residual
multiple mediastinal lymph node metastases. In conclusion,
our data show that there is not a single endocrine test or
imaging procedure accurate enough to diagnose and localize
occult ectopic ACTH-secreting bronchial carcinoids. Ra-
dioguided surgery appears to be promising in the presence of
multiple tumor foci and previous incomplete removal of the
tumor. (J Clin Endocrinol Metab 88: 1029–1035, 2003)
THE ECTOPIC ACTH syndrome accounts for 5–10% of allcases of ACTH-dependent hypercortisolism, and bron-
chial carcinoids are the most frequent occult source of ectopic
ACTH (1). Unlike patients with highly aggressive ACTH-
secreting tumors, patients bearing small nonaggressive tu-
mors, such as bronchial carcinoids, may have a clinical
course indistinguishable from that of patients with Cushing’s
disease (2).
As patients with both eutopic and ectopic sources of
ACTH may have misleading results when tested with the
most accurate noninvasive biochemical tests (i.e. the CRH
and high dose dexamethasone suppression tests), differential
diagnosis relies on the results of ACTH sampling in inferior
petrosal sinuses. However, this procedure does not localize
the source of ectopic ACTH secretion, whose identification is
based on imaging techniques such as computed tomography
(CT) and/or magnetic resonance imaging (MRI). Recently
[111In]pentetreotide scintigraphy ([111In]PS) has been pro-
posed as a useful tool to localize the source of ACTH in
patients with a high suspicion of ectopic syndrome. How-
ever, the radiological and scintigraphic techniques may show
limited accuracy in detecting ACTH-secreting bronchial car-
cinoids mainly because of their small size (3–6).
In the literature, patients with bronchial carcinoids are
often included in heterogeneous series of ectopic ACTH-
secreting tumors, in whom only some of the aforementioned
diagnostic procedures have been performed. We report our
experience in six patients with ascertained, truly occult, bron-
chial carcinoid, in each of whom hormonal, conventional
imaging, and scintigraphic evaluations were performed.
Subjects and Methods
Of 67 patients with endogenous hypercortisolism seen at our insti-
tution between 1991 and 1999, 6 had the final diagnosis of ACTH-
secreting bronchial carcinoid, and they were included in this study.
These patients (3 women and 3 men), aged 25–65 yr, were referred to
the Endocrine Unit for recently diagnosed, severe hypercortisolism; one
patient (no. 6) had been previously treated elsewhere by pituitary mi-
crosurgery. Epidemiological and clinical data together with basal hor-
mone levels are reported in Table 1. Each patient showed typical stig-
mata of Cushing’s syndrome; particularly 5 of 6 patients complained of
severe myopathy, resulting in intense weakness, preventing them from
walking, 5 of 6 had hypertension, and 3 of 6 diabetes. Hirsutism was
present in all female patients, and the 2 premenopausal women were
amenorrheic. Each patient had hypokalemia requiring potassium iv
supplementation. Marked osteopenia with vertebral collapses was doc-
umented in 4 patients; because of that all of them needed a brace.
In all patients the presence of ACTH-dependent hypercortisolism was
established on the basis of supranormal excretion of 24-h urinary cortisol
in presence of supranormal ACTH concentration (evaluated, in each
instance, in at least three blood samples withdrawn at 20-min intervals).
All patients underwent CRH stimulation testing (100 g ovine CRH, iv;
CLINALFA, Laufelfingen, Switzerland) for the determination of plasma
ACTH and cortisol (blood samples at 15, 0, 15, 30, 45, 60, 90, and 120
min) and high dose dexamethasone suppression test. Four patients
underwent the 2-d test with determination of urinary free cortisol, and
two patients underwent the overnight test (8 mg dexamethasone, orally,
Abbreviations: BIPSS, Bilateral inferior petrosal sinus sampling; C/P,
central to peripheral; CT, computed tomography; MRI, magnetic reso-
nance imaging; PS, pentetreotide scintigraphy.
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administered between 2300–2400 h, with blood sampling at 0830 h
pretreatment and 0900 h the next day). Five patients underwent des-
mopressin stimulation test for ACTH and cortisol determinations (5 g,
iv; Minirin/DDAVP, Ferring Pharmaceuticals Ltd., Malmo, Sweden);
blood was sampled at –15, 0, 15, 30, 60, and 90 min after drug admin-
istration. CRH and desmopressin stimulation tests for ACTH determi-
nation were performed later in the follow-up, after bilateral adrenalec-
tomy in patient 6.
The criteria used to establish the presence of pituitary responsiveness
to CRH were an increase in mean plasma ACTH at 15–30 min greater
than 35% and/or an increase in mean plasma cortisol at 30–45 min
greater than 20% above basal levels (7). For the desmopressin test the
criteria used were an increase in mean plasma ACTH at 15–30 min
greater than 35% and an increase in mean plasma cortisol at 30–60 min
greater than 20% above basal levels. The criterion used to establish
pituitary-adrenal suppressibility after high dose dexamethasone was a
fall in plasma cortisol or in urinary free cortisol excretion by at least 50%
or 90%, respectively (8, 9).
All patients underwent bilateral, simultaneous catheterization of in-
ferior petrosal sinuses for ACTH determination with samples taken at
–15, 0, 1, 3, 5, and 10 min after CRH administration, as previously
described (10). In each case the procedure was performed during the
initial diagnostic work-up while the patients had severe hypercorti-
solism, before any medical treatment was started. According to the
generally accepted criteria, a central to peripheral (C/P) plasma ACTH
gradient lower than 2 in basal conditions and/or 3 after CRH was
considered consistent with the presence of ectopic ACTH secretion (11).
In addition, all patients had ACTH and cortisol assessed after a test dose
of 0.1 mg octreotide, sc, to assess the effectiveness of the drug in in-
hibiting hormonal secretion. ACTH and cortisol changes after drug
administration were compared with the hormone values recorded at the
same time points during saline infusion on a previous day. The markers
of neuroendocrine neoplasia (urinary 5-hydroxyindolacetic acid, serum
neuron-specific enolase, and calcitonin) were assessed in each patient.
All patients underwent pituitary MRI.
Imaging studies included CT of the chest and the abdomen. Section
thickness was 5 mm in the chest and upper abdomen and 10 mm in lower
abdomen and pelvis. Oral contrastrographic media and iv nonionic
water soluble contrast were given at the radiologist’s discretion. In each
case the radiologist was aware of the suspicion of ectopic ACTH syn-
drome. MRI of the chest was performed in two cases (no. 2 and 4).
Total body [111In]PS was performed at least once in all patients. The
scans were performed with multiple planar and single photon emission
CT images of the head, neck, chest, and abdomen obtained 4 and 24 h
after iv administration of 122 MBq 111In-labeled pentetreotide. The as-
sessment of tracer accumulation was made by the same nuclear medicine
physician.
Results
Hormonal data
All patients had high serum and urinary cortisol levels and
supranormal plasma ACTH values (Table 1). CRH adminis-
tration did not induce any ACTH and/or cortisol increase in
four patients; one patient (no. 5) had a 38% increase in ACTH,
and another one (no. 2) had a 30% increase in cortisol. Desmo-
pressin administration determined an ACTH and cortisol re-
sponse in two of five patients (no. 4 and 5). Two of six patients
showed dexamethasone-induced suppression (Table 2).
None of the patients showed a central to peripheral ACTH
gradient greater than 2 in basal conditions or greater than 3
after CRH stimulation during bilateral inferior petrosal sinus
sampling (BIPSS). The absence of a central to peripheral
ACTH gradient was not considered conclusive for ectopic
ACTH in patient 2 because of the presence of a right plex-
iform inferior petrosal sinus. Compared with saline infusion,
acute administration of octreotide induced decreases in
plasma ACTH and cortisol greater than 30% in three patients
(no. 2–4) (Table 2). Apart from BIPSS, endocrine testing sug-
gested ectopic ACTH secretion in three of six patients (no. 1,
3, and 4). The markers of neuroendocrine neoplasia were
negative in all patients.
Imaging
Data on the timing and results of the imaging are reported
in Table 3. Pituitary MRI was negative in four patients. It
TABLE 2. Results of hormonal dynamic evaluation and BIPSS in the patients studied
Case
CRH test (100 g ev) DDAVP test (5 g ev) SMS test (100 g sc) HD-DEXA suppression test BIPSS
post-CRH C/P
ACTH ratio
ACTH %
increase
Cortisol %
increase
ACTH %
increase
Cortisol %
increase
ACTH %
decrease
Cortisol %
decrease
8  8 mga Overnight
8 mgb
1 3 15 8 11 29.2 15.8 0% 0.9
2 1 30 5 55.7 71.1 85% 1
3 0 7 30.3 57.1 60% 1
4 1 6 77 37 40.6 36.7 23% 1
5 38 8 377 59 54.4 2.7 50% 1
6c 0 23.6 26.6 25.9 91% 2.3
a Inhibition of 24-h UFC excretion.
b Inhibition of morning serum cortisol.
c CRH and DDAVP tests performed after adrenalectomy; SMS test, HD-DEXA test, and BIPSS performed after unsuccessful pituitary
microsurgery and before adrenalectomy.
TABLE 1. Epidemiological, clinical data and basal hormonal evaluation of the patients studied
Case Sex/age Hypertension Diabetes Hypokalemia(3.0 mEq/liter)
Vertebral
collapses
ACTH
(pmol/liter)a
Cortisol
(nmol/liter)a
Urinary free cortisol
(nmol/d)
1 M/33 Yes Yes Yes No 31 938 5794
2 M/25 No No Yes Yes 30 745 3523
3 F/65 Yes No Yes Yes 38 1231 1628
4 F/28 Yes Yes Yes Yes 38 938 9850
5 F/27 Yes Yes Yes Yes 23 690 1007
6 M/29 Yes No Yes No 41 979 2566
Plasma ACTH normal range, 2–11.5 pmol/liter; morning cortisol normal range, 220–690 nmol/liter; urinary free cortisol normal range,
27–220 nmol/d.
a Mean of at least three morning determinations.
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showed an equivocal hypointense area suspicious for a mi-
croadenoma in one patient (no. 2) and became suspicious for
a microadenoma during the follow-up in another patient (no.
5). At the time of the diagnosis of hypercortisolism, none of
the patients had CT (n  6) or MRI (n  1) evidence of an
ectopic source of ACTH. Two (no. 1 and 4) of four patients
who underwent PS showed evidence of abnormal uptake in
the chest. This finding suggested that targeted CT scans
should be performed in these two patients.
Radiological results
Eventually, CT scan disclosed a chest lesion in all patients.
In two cases it was the only imaging technique to reveal the
presence of a lesion suggestive for bronchial carcinoid (no. 3
and 5) 8 and 50 months, respectively, after the initial diag-
nosis. In another two cases (no. 1 and 4), the CT scan, focused
on the area of interest, confirmed a previous abnormal PS 12
and 1 month after the initial diagnosis. In patients 2 and 6,
the CT scan of the chest identified the ectopic source of
ACTH, which was confirmed by PS in the same period, 8 yr
after an incorrect initial diagnosis of pituitary adenoma. One
or two negative CT scans preceded radiological demonstra-
tion of the ectopic source of ACTH in each patient.
Scintigraphic results
PS identified four of six ACTH-secreting tumors; in two
cases scintigraphy was not performed at the time of diag-
nosis, but followed radiological demonstration of the lesion
(no. 2 and 6). A pentetreotide scan, performed twice in two
patients (no. 3 and 5), was repeatedly negative even after
radiological demonstration of bronchial tumors. In no case
did PS give false positive results. There was no correlation
between the effect of acute administration of octreotide on
hormone secretion and tracer uptake by PS (Table 4).
Management and outcome
Data on management and outcome are reported in Table
3. After referral, based on incorrect diagnoses, two patients
(no. 2 and 5) underwent unsuccessful pituitary microsur-
gery; in both cases there was no clear evidence of adenoma,
although the tissue removed at surgery was intensely im-
munoreactive for ACTH in one case (no. 2). Subsequently,
one of these patients (no. 5) was treated with pituitary ra-
diotherapy and adrenal steroidogenesis inhibitors, whereas
the other (no. 2) underwent bilateral adrenalectomy.
Pending the identification of the ectopic source of ACTH,
bilateral adrenalectomy was performed in two additional
patients (no. 1 and 6), who showed limited effectiveness of
medical treatment with ketoconazole and/or octreotide at
tolerated doses, and in another patient (no. 4), who had
persistent hypercortisolism after removal of the bronchial
carcinoid.
In all patients a bronchial carcinoid was finally found and
removed (Table 3). ACTH immunoreactivity of the tissue
was documented in all but one case (no. 4). Lymph node
metastases were detected at surgery in five of six patients;
multiple node metastases were removed in two subsequent
operations in patient 4 (see below). Patient 2 underwent
chemotherapy because of evidence of atypical carcinoid. A
cure was achieved after removal of the primary lesion and
metastases in all patients 8–96 months after the diagnosis of
hypercortisolism.
In one patient (no. 4) the disease persisted after the first
operation; the postoperative persistence of tracer uptake at
PS indicated the presence of pathological tissue in the me-
diastinum not detected at surgery and only subsequently
confirmed by radiological studies. The patient underwent a
second operation, after which scintigraphic and radiological
evidence of residual disease persisted. Lastly, the patient
underwent radioguided surgery using an handheld  probe
24 h after iv administration of a tracer dose of radiolabeled
[111In]DTPA-d-Phe1-pentetreotide that allowed detection
and removal of residual multiple mediastinal lymph node
metastases. Cure and no more evidence of tracer uptake at
PS followed. Two additional patients (no. 1 and 2), with
positive preoperative scintigraphy, repeated this procedure
after removal of the ectopic source of ACTH to exclude the
presence of residual tumor or distant metastases; in both
cases no uptake of the tracer was recorded.
Eventually, a clear-cut reduction of plasma ACTH levels
to normal (no. 1 and 2) or subnormal, low normal (no. 3–6)
values was observed in all patients (Table 5); the two who did
not undergo adrenalectomy (no. 3 and 5) showed postoper-
ative hypoadrenalism after removal of the bronchial carci-
noid. At follow-up patients 2, 3, 4, 5, and 6 were free of
disease at 24, 78, 15, 9, and 3 months after surgery, respec-
tively. In patient 1 an increase in plasma ACTH with no
radiological or scintigraphic evidence of tumor tissue was
observed 1 month after surgery.
Discussion
The present study reports a series of patients with hyper-
cortisolism due to an occult ACTH-secreting bronchial car-
cinoid; the patients were evaluated at the same institution.
There are several case reports in the literature, two large
surgical series and a review of previously reported cases,
where the diagnostic endocrine work-up was not extensively
performed or reported (1, 12, 13). Although not representa-
tive of all patients with this disease, the cases reported here
show the limits of single diagnostic procedures and offer the
opportunity to evaluate their roles in clinical practice.
It is often reported that patients with occult ectopic ACTH
syndrome do not show distinctive clinical features compared
with patients with Cushing’s disease (2, 14, 15). The severity
of the clinical and biochemical expression of hypercorti-
solism observed in our patients suggests that occult ectopic
Cushing’s syndrome due to bronchial carcinoid may be more
severe than pituitary-dependent disease. As previously re-
ported (5, 6, 13), the age at presentation of disease was less
than 33 yr in all but one of our patients, confirming that
patients with ACTH-secreting bronchial carcinoid are gen-
erally younger than patients with ectopic sources of ACTH
located elsewhere (1).
Our results confirm that dynamic endocrine testing may
be misleading in bronchial carcinoids. In fact, two patients in
the present series were responsive to CRH administration,
and one of them was also responsive to dexamethasone sup-
Loli et al. • Occult, ACTH-Secreting Bronchial Carcinoids J Clin Endocrinol Metab, March 2003, 88(3):1029–1035 1031
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 15 July 2014. at 04:16 For personal use only. No other uses without permission. . All rights reserved.
T
A
B
L
E
3.
C
li
n
ic
al
an
d
pa
th
ol
og
ic
al
w
or
k-
u
p
of
th
e
pa
ti
en
ts
st
u
di
ed
C
as
e
D
at
e
w
or
k-
u
p
P
en
te
tr
eo
ti
de
sc
an
re
su
lt
R
ad
io
lo
gi
ca
l
im
ag
in
g
H
is
to
ry
an
d
ou
tc
om
e
P
at
h
ol
og
ic
al
an
d
im
m
u
n
oh
is
to
ch
em
ic
al
di
ag
n
os
is
1
Ja
n
-9
9
R
ig
h
t
m
id
ce
n
tr
al
lu
n
g
fi
el
d;
on
e
fo
cu
s
N
eg
at
iv
e
ab
do
m
in
al
an
d
ch
es
t
C
T
M
ed
ic
al
tr
ea
tm
en
t
(k
et
oc
on
az
ol
e
pl
u
s
oc
tr
eo
ti
de
fo
r
3
m
on
th
s)
M
ay
-9
9
N
eg
at
iv
e
ch
es
t
C
T
B
il
at
er
al
ad
re
n
al
ec
to
m
y
Ja
n
-0
0
P
os
it
iv
e
ch
es
t
C
T
;
ri
gh
t
m
id
ce
n
tr
al
lu
n
g
n
od
u
le
12
m
m
M
ar
-0
0
C
u
re
d
af
te
r
ri
gh
t
lu
n
g
u
pp
er
lo
be
ct
om
y
T
yp
ic
al
ca
rc
in
oi
d,
13
m
m
;
A
C
T
H

;
ly
m
ph
n
od
e
m
et
as
ta
si
s
in
1/
6
N
1
Ju
n
-0
0
N
eg
at
iv
e
N
eg
at
iv
e
ch
es
t
C
T
N
or
m
al
iz
at
io
n
of
A
C
T
H
le
ve
ls
2a
M
ar
-9
1
N
eg
at
iv
e
ab
do
m
in
al
an
d
ch
es
t
C
T
;
n
eg
at
iv
e
ch
es
t
M
R
I
M
ed
ic
al
tr
ea
tm
en
t
ke
to
co
n
az
ol
e
pl
u
s
oc
tr
eo
ti
de
fo
r
2
m
on
th
s
A
u
g-
91
E
qu
iv
oc
al
pi
tu
it
ar
y
M
R
I
U
n
su
cc
es
sf
u
l
pi
tu
it
ar
y
su
rg
er
y
S
u
gg
es
ti
ve
bu
t
n
ot
co
n
cl
u
si
ve
fo
r
pi
tu
it
ar
y
ad
en
om
a
A
C
T
H

N
ov
-9
1
N
eg
at
iv
e
ch
es
t
C
T
B
il
at
er
al
ad
re
n
al
ec
to
m
y
A
u
g/
S
ep
-9
9
R
ig
h
t
m
id
ce
n
tr
al
lu
n
g;
tw
o
fo
ci
P
os
it
iv
e
ch
es
t
C
T
;
ri
gh
t
lu
n
g
u
pp
er
lo
be
n
od
u
le
20
m
m
an
d
h
il
ar
ly
m
ph
n
od
e
R
ig
h
t
lu
n
g
u
pp
er
lo
be
ct
om
y.
N
or
m
al
iz
at
io
n
of
pl
as
m
a
A
C
T
H
le
ve
ls
A
ty
pi
ca
l
ca
rc
in
oi
d,
15
m
m
;
A
C
T
H

,
N
S
E

,
C
gA

,
C
C
K
19

;
ly
m
ph
n
od
e
m
et
as
ta
se
s
in
3/
4
N
1
an
d
4/
4
N
2
O
ct
-9
9
N
eg
at
iv
e
N
eg
at
iv
e
to
ta
l
bo
dy
C
T
C
h
em
ot
h
er
ap
y.
P
er
si
st
en
ce
of
n
or
m
al
A
C
T
H
va
lu
es
3a
Ja
n
-9
4
N
eg
at
iv
e
N
eg
at
iv
e
ch
es
t-
ab
do
m
en
C
T
M
ed
ic
al
tr
ea
tm
en
t:
ke
to
co
n
az
ol
e
pl
u
s
oc
tr
eo
ti
de
fo
r
8
m
on
th
s
S
ep
-9
4
N
eg
at
iv
e
P
os
it
iv
e
ch
es
t
C
T
:
ri
gh
t
lu
n
g
u
pp
er
lo
be
n
od
u
le
20
m
m
U
pp
er
ri
gh
t
lu
n
g
lo
be
ct
om
y.
R
ed
u
ct
io
n
of
pl
as
m
a
A
C
T
H
to
su
bn
or
m
al
le
ve
ls
;
po
st
op
er
at
iv
e
h
yp
oa
dr
en
al
is
m
la
st
in
g
on
e
ye
ar
T
yp
ic
al
ca
rc
in
oi
d,
15
m
m
;
A
C
T
H

,
5H
T

,
C
gA

A
pr
-0
1
N
eg
at
iv
e
ch
es
t
C
T
N
or
m
al
A
C
T
H
le
ve
ls
4
D
ec
-9
5
R
ig
h
t
pa
ra
ca
rd
ia
c,
tw
o
fo
ci
N
eg
at
iv
e
ch
es
t-
ab
do
m
en
C
T
M
ed
ic
al
tr
ea
tm
en
t:
ke
to
co
n
az
ol
e
pl
u
s
oc
tr
eo
ti
de
fo
r
1
m
on
th
Ja
n
-9
6
P
os
it
iv
e
ch
es
t
C
T
:
ri
gh
t
lu
n
g
m
id
ce
n
tr
al
n
od
u
le
1
cm
E
xc
is
io
n
of
ri
gh
t
lu
n
g
in
fe
ri
or
lo
be
n
od
u
le
;
pe
rs
is
te
n
ce
of
di
se
as
e
T
yp
ic
al
ca
rc
in
oi
d,
18
m
m
;
A
C
T
H

M
ar
-9
6
B
il
at
er
al
ad
re
n
al
ec
to
m
y
A
pr
-9
6
R
ig
h
t
pa
ra
ca
rd
ia
c
on
e
fo
cu
s
O
ct
-9
6
N
eg
at
iv
e
ch
es
t
C
T
Ju
ly
-9
8
R
ig
h
t
pa
ra
ca
rd
ia
c
tw
o
fo
ci
P
os
it
iv
e
ch
es
t
C
T
:
re
tr
o-
st
er
n
al
n
od
u
le
.
P
os
it
iv
e
ch
es
t
M
R
I:
tw
o
re
tr
os
te
rn
al
n
od
u
le
s
A
pr
/J
u
n
-9
9
P
os
it
iv
e
ch
es
t
C
T
:
tw
o
re
tr
o-
st
er
n
al
n
od
u
le
s
T
h
ym
ec
to
m
y.
P
er
si
st
en
ce
of
su
pr
an
or
m
al
A
C
T
H
M
u
lt
ip
le
th
ym
ic
m
ic
ro
fo
ci
of
n
eu
ro
en
do
cr
in
e
A
C
T
H

tu
m
or
;
ly
m
ph
n
od
e
m
et
as
ta
si
s
23
m
m
N
ov
-9
9
R
ig
h
t
pa
ra
ca
rd
ia
c
on
e
fo
cu
s
(u
pp
er
m
ed
ia
st
in
u
m
)
P
os
it
iv
e
ch
es
t
C
T
:
an
te
ri
or
m
ed
ia
st
in
u
m
n
od
u
le
10
m
m
F
eb
/A
pr
-0
0
P
os
it
iv
e
ch
es
t
C
T
:
m
u
lt
ip
le
m
ed
ia
st
in
al
pa
th
ol
og
ic
ly
m
ph
n
od
es
R
ad
io
gu
id
ed
th
or
ac
os
co
pi
c
ex
ci
si
on
of
m
ed
ia
st
in
al
ly
m
ph
n
od
e
m
et
as
ta
se
s.
R
ed
u
ct
io
n
of
A
C
T
H
to
su
bn
or
m
al
le
ve
ls
M
u
lt
ip
le
ly
m
ph
n
od
e
m
et
as
ta
se
s
of
n
eu
ro
en
do
cr
in
e
tu
m
or
3–
15
m
m
Ju
n
-0
0
N
eg
at
iv
e
S
u
bn
or
m
al
A
C
T
H
le
ve
ls
5
N
ov
/D
ec
-9
5
N
eg
at
iv
e
N
eg
at
iv
e
ch
es
t-
ab
do
m
en
C
T
.
N
eg
at
iv
e
pi
tu
it
ar
y
M
R
I
M
ed
ic
al
tr
ea
tm
en
t:
ke
to
co
n
az
ol
e
fo
r
3
m
on
th
s.
S
po
n
ta
n
eo
u
s
re
m
is
si
on
of
C
u
sh
in
g
an
d
h
yp
oc
or
ti
so
li
sm
fo
r
18
m
on
th
s
M
ar
-9
6
N
eg
at
iv
e
to
ta
l
bo
dy
C
T
.
S
ep
-9
8
R
ec
u
rr
en
ce
of
h
yp
er
co
rt
is
ol
is
m
N
ov
-9
8
E
qu
iv
oc
al
pi
tu
it
ar
y
M
R
I
P
it
u
it
ar
y
m
ic
ro
su
rg
er
y.
P
er
si
st
en
ce
of
h
yp
er
co
rt
is
ol
is
m
.
M
ed
ic
al
tr
ea
tm
en
t:
ke
to
co
n
az
ol
e
A
C
T
H

ce
ll
s,
n
ot
co
n
cl
u
si
ve
fo
r
ad
en
om
a
1032 J Clin Endocrinol Metab, March 2003, 88(3):1029–1035 Loli et al. • Occult, ACTH-Secreting Bronchial Carcinoids
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 15 July 2014. at 04:16 For personal use only. No other uses without permission. . All rights reserved.
pression. This finding can be expected if one considers that
the reported specificity of the CRH test ranges from 88–100%
whether cortisol or the ACTH responses are considered (7),
and the specificity of the high dose dexamethasone suppres-
sion test ranges from 60–100% (3). The choice of cut-off
points affects both the sensitivity and the specificity of a test,
and the decision to use less stringent criteria improves sen-
sitivity at the expense of specificity. In our series patient 5
would not have been considered to show suppression on a
more recent evaluation of a high dose dexamethasone sup-
pression test, suggesting a more strict cut-off point for sup-
pression to avoid misdiagnosing Cushing’s disease (16).
Even in this case complete diagnostic accuracy is not en-
sured, as shown by one patient (no. 6) who had 91% sup-
pression on high dose dexamethasone. This is a teaching
point that might indicate that even more stringent criteria are
bound to lose discriminatory power when the number of
patients observed and experience increase, and that the re-
sults near the cut-off points should be viewed with some
skepticism.
Even if theoretically very uncommon, the occurrence of
ACTH-secreting bronchial carcinoids that are suppressed on
a high dose dexamethasone suppression test and exhibit
responsiveness to CRH does exist in practice, suggesting that
one cannot rely on these dynamic tests only (17, 18).
The response to desmopressin administration observed in
two patients confirms that this test, as already suggested by
others (19–21), is unreliable in the differential diagnosis of
Cushing’s syndrome. To date it is not known whether the
overexpression of vasopressin receptor subtypes V2 and V3,
which mediate the ACTH response to desmopressin, is lim-
ited to bronchial carcinoids or is extended to other ectopic
ACTH sources. Reportedly, the most accurate test in the
differential diagnosis of ACTH-dependent Cushing’s syn-
drome is BIPSS (11, 22, 23).
Our data support this evidence, in that no patients showed
TABLE 4. Comparison between hormonal response to acute
octreotide administration and results of pentetreotide scintigraphy
Case Octreotide test(100 g sc)
111In-pentetreotide
scintigraphy
1 No response Positive
2 Response Positive
3 Response Negative
4 Response Positive
5 No response Negative
6 No response Positive
TABLE 5. Plasma ACTH values (picomoles per liter) at basal
evaluation and after thoracic surgery
Case Baseline After tumorresection
1a 31 8.8
2a 30 5.5
3 38 1.8
4a,b 38 1.5
5 23 1.3
6a 41 2.6
Plasma ACTH normal range, 2–11.5 pmol/liter.
a Patient previously adrenalectomized.
b ACTH value after radioguided mediastinal surgery.
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a C/P ACTH gradient greater than the commonly accepted
cut-off point (11). However, one of our patients did show a
C/P ratio that was the highest ever reported in the ectopic
ACTH syndrome (11), even higher than the value proposed
by Findling et al. (22). A C/P ACTH gradient suggestive of
pituitary-dependent disease has been reported in patients
with ectopic CRH and/or CRH-ACTH production (13, 18).
This possibility cannot be excluded in our patient, because
immunohistochemical determination of CRH within the tu-
mor was not performed. In any case, the existence of the
ectopic CRH-ACTH syndrome potentially reduces the reli-
ability of inferior petrosal sinus sampling. In addition, this
procedure may be less reliable in the presence of plexiform
or hypoplastic inferior petrosal sinuses (24). The presence of
a plexiform petrosal sinus led us to discount the absence of
a C/P ACTH gradient in one patient, contributing to an
incorrect diagnosis of Cushing’s disease.
Even in the context of imaging, the differentiation between
eutopic and ectopic (occult) ACTH syndromes may be dif-
ficult. Small bronchial carcinoids are sometimes undetected
or identified late because of the inner location that makes
them look like normal vessels. In the particular setting of
ACTH-secreting bronchial carcinoids, the late recognition of
the ectopic source of ACTH exposes the patient to unduly
prolonged hypercortisolism or to adrenalectomy when med-
ical therapy has limited efficacy. It is still debated whether
chest MRI has an additional potential value with respect to
CT in detecting bronchial carcinoids. This procedure was
performed in only two patients of the present series, and it
did not give additional information, but we cannot exclude
that it might be useful in some cases (5, 25–27).
[111In]PS has been proposed as a means to localize the
source of ACTH in patients with a high suspicion of ectopic
syndrome and negative results of common imaging tech-
niques (28, 29). Bronchial carcinoids, as most of the neuroen-
docrine tumors, express somatostatin receptor subtype 2,
which can be visualized by PS. In our experience the sensi-
tivity of this procedure was 67%, similar to that reported by
Torpy et al. (6) in four bronchial carcinoids, but lower than
that reported by Krenning et al. (30) in a very large series of
carcinoids with different sites of origin. This finding and the
very low sensitivity of [111In]PS reported by Tabarin et al. (5)
in three bronchial carcinoids, might suggest that these tu-
mors express somatostatin receptor subtype 2 less frequently
than carcinoids originating at other sites, although the small
size of the tumors might be another explanation. The spec-
ificity of PS is limited according to different reports (5, 6, 30);
no false positive results were recorded in the present series.
As reported by Tabarin et al. (5), the present study confirms
that the repetition of PS, even if performed in a drug-induced
eucortisolemic state or several months after the first scinti-
graphic examination, is useless in patients with previous
negative scintigraphic study.
When conventional imaging is negative, PS might help in
localizing the tumor a posteriori by CT, focusing on a partic-
ular area. A surgical approach based exclusively on scinti-
graphic evidence of the tumor is not commonly accepted,
taking into consideration the limits of specificity of this
procedure.
In patients with positive PS tumors, the possibility to as-
sess the complete removal of pathological tissue after surgery
is of particular clinical relevance. In four of our patients
surgical success was confirmed by the disappearance of
tracer uptake as well as the parallel decrease in plasma
ACTH. The persistence of both supranormal ACTH levels
and tracer uptake was documented in the only patient with
incomplete removal of pathological tissue due to the pres-
ence of multiple tumor foci.
In our experience the presence of multiple tumor foci and
previous incomplete removal of tumor indicated the use of
PS for intraoperative detection and removal of neuroendo-
crine tissue; to date limited data are available to suggest an
extensive use of this procedure beyond this indication. The
absence of correlation between tracer uptake by PS and
the response to octreotide administration observed in the
present study, already reported in the literature, suggests
that the acute test cannot be used to select patients to submit
to PS (31–33).
Although typically indolent, bronchial carcinoids are gen-
erally considered to be low grade malignancies, as shown by
their ability to metastasize. Reportedly, the prevalence of
node metastases in typical carcinoids ranges from 2.3–11%,
lower than the range reported for atypical carcinoids (27–
66%) (34, 35). In the present series, five of six tumors were
typical; nonetheless, the prevalence of locoregional node me-
tastases was 80%, and that of mediastinal nodes was 20%.
This figure is higher than that reported for non-ACTH-
secreting bronchial carcinoids and is comparable to those
reported by Pass et al. (12) and Shrager et al. (13). This finding
seems to confirm the evidence reported by Shrager et al. (13)
of a much greater metastatic potential for ACTH-secreting
than for hormonally quiescent typical carcinoids and sup-
ports the recommendation for routine, complete mediastinal
lymph node dissection. Unlike nonsecreting tumors, in
ACTH-secreting bronchial carcinoids, the ACTH concentra-
tion might be used as a marker of persistence of disease after
surgery. In all of our patients ACTH clearly decreased post-
operatively to low normal or normal values, but a correct
cut-off point for the interpretation of a postoperative ACTH
value cannot be easily set. In general, the persistence of mid
to high normal ACTH values immediately after surgery in a
hypercortisolemic patient might indicate residual disease,
because in this setting normal corticotropes are suppressed.
However, as in the case of Cushing’s disease treated by
pituitary microsurgery, a minority of cases show that this is
not an absolute rule. As for ACTH-secreting bronchial car-
cinoids, in studies where post operative ACTH is measured,
a decrease to normal values is considered a signal of removal
of disease (12, 36–38). Undetectable postoperative ACTH
values were reported only in a patient with ectopic ACTH
syndrome due to retropancreatic carcinoid tumor who had
been previously hypophysectomized (18). Another issue that
should perhaps be taken into account is that four of our
patients and others in the studies mentioned above had pre-
viously undergone bilateral adrenalectomy and were receiv-
ing replacement therapy with glucocorticoids (cortisone in
all of our cases, two of whom had undergone adrenalectomy
8 and 9 yr before thoracic surgery); it is debatable whether
in this setting one should expect ACTH suppression.
In conclusion, the present study shows that there is not a
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single endocrine test or imaging procedure accurate enough
to diagnose and localize small, occult, ectopic ACTH-secret-
ing bronchial carcinoids. This suggests the opportunity of an
extensive diagnostic approach. In our experience, plasma
ACTH is a good marker of the presence or persistence of
disease. ACTH-secreting bronchial carcinoids show a greater
potential for node metastases than nonsecreting bronchial
tumors; this is why a search for all diseased tissue is rec-
ommended; the use of an intraoperative  counter to identify
PS-positive tissue appears to be a promising procedure.
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